🇺🇸 Subgam in United States
36 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 36
Most-reported reactions
- Erythema — 7 reports (19.44%)
- Chronic Kidney Disease — 4 reports (11.11%)
- Tubulointerstitial Nephritis — 4 reports (11.11%)
- Burning Sensation — 3 reports (8.33%)
- Chest Pain — 3 reports (8.33%)
- Infusion Site Erythema — 3 reports (8.33%)
- Infusion Site Pain — 3 reports (8.33%)
- Infusion Site Swelling — 3 reports (8.33%)
- Lip Pain — 3 reports (8.33%)
- Lip Ulceration — 3 reports (8.33%)
Other Other approved in United States
Frequently asked questions
Is Subgam approved in United States?
Subgam does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Subgam in United States?
Bio Products Laboratory is the originator. The local marketing authorisation holder may differ — check the official source linked above.